Zymeworks Inc. (ZYME) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $24.54: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Zymeworks is a clinical-stage biopharma pursuing a royalty aggregation strategy with zanidatamab (Ziihera) as its lead asset, approved for HER2+ biliary tract cancer and licensed to Jazz (global ex-Asia) and BeOne (Asia). Revenue consists of milestones ($69.9M in 2025) and... Read more
Sell if holding. Engine safety override at $24.54: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent Developments — Zymeworks Inc.
Latest news
- Zymeworks Announces $125M Buyback Plan — benzinga May 14, 2026 positive
- Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $34 — benzinga May 8, 2026 positive
- Zymeworks Q1 EPS $(0.59) Down From $(0.30) YoY, Sales $2.408M Down From $27.110M YoY — benzinga May 7, 2026 negative
- HC Wainwright & Co. Reiterates Buy on Zymeworks, Maintains $46 Price Target — benzinga Apr 23, 2026 positive
- Zymeworks Reveals New Phase 1 Data for ZW191, A Folate Receptor Alpha-Targeting ADC At AACR Annual Meeting 2026; ZW191 D — benzinga Apr 21, 2026 positive
Generated 2026-05-20T20:21:22Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyJazz and BeOne (zanidatamab partners)10-K Item 1A: 'We depend on our collaborative relationships with Jazz, BeOne and J&J to further develop and commercialize zanidatamab'
- HIGHpipelinezanidatamab (Ziihera)10-K Item 1A: 'We have only one product approved for commercial sale ... other than the receipt of royalties relating to sales of zanidatamab'
Material Events(8-K, last 90d)
- 2026-04-01Item 5.02LOWKristin Stafford appointed as EVP, CFO of Zymeworks effective April 1, 2026. Prior role: SVP, Chief Accounting Officer at Royalty Pharma plc since December 2018. No family relationships or conflicts cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -126.3%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $24.54: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $22.72. Score 5.3/10, moderate confidence.
Take-profit target: $34.93 (+43.0% upside). Prior stop was $22.72. Stop-loss: $22.72.
Concentration risk — Counterparty: Jazz and BeOne (zanidatamab partners); Concentration risk — Pipeline: zanidatamab (Ziihera); Quality below floor (2.2 < 4.0).
Zymeworks Inc. trades at a P/E of N/A (forward 47.4). TrendMatrix value score: 4.3/10. Verdict: Sell.
20 analysts cover ZYME with a consensus score of 4.3/5. Average price target: $40.
What does Zymeworks Inc. do?Zymeworks is a clinical-stage biopharma pursuing a royalty aggregation strategy with zanidatamab (Ziihera) as its lead...
Zymeworks is a clinical-stage biopharma pursuing a royalty aggregation strategy with zanidatamab (Ziihera) as its lead asset, approved for HER2+ biliary tract cancer and licensed to Jazz (global ex-Asia) and BeOne (Asia). Revenue consists of milestones ($69.9M in 2025) and royalties on Ziihera sales; wholly-owned pipeline includes ADCs (ZW191, ZW251) and bispecifics in Phase 1.